Summary
1.19 -0.03(-2.48%)09/06/2024
ATAI Life Sciences N.V. (ATAI)
ATAI Life Sciences N.V. (ATAI)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -2.46 | -8.46 | -12.82 | -19.32 | -40.20 | -17.36 | 0.00 | -98.07 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 1.19 | |
| Open | 1.23 | |
| High | 1.24 | |
| Low | 1.18 | |
| Volume | 441,960 | |
| Change | -0.03 | |
| Change % | -2.46 | |
| Avg Volume (20 Days) | 492,632 | |
| Volume/Avg Volume (20 Days) Ratio | 0.90 | |
| 52 Week Range | 1.03 - 2.85 | |
| Price vs 52 Week High | -58.25% | |
| Price vs 52 Week Low | 15.53% | |
| Range | -3.25 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 200 | |
| EBIDTA | 0 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | 0.0000 | |
| WallStreet Target Price | 30.62 | |
| Book Value | 2.8380 | |
| Earnings Per Share | -3.9390 | |
| EPS Estimate Current Quarter | -0.2100 | |
| EPS Estimate Next Quarter | -0.2400 | |
| EPS Estimate Current Year | -0.8400 | |
| EPS Estimate Next Year | -0.9900 | |
| Diluted EPS (TTM) | -3.9390 | |
| Revenues | ||
| Profit Marging | 0.0000 | |
| Operating Marging (TTM) | -7.7947 | |
| Return on asset (TTM) | 0.0000 | |
| Return on equity (TTM) | -99,999.9900 | |
| Revenue TTM | 20,146,000 | |
| Revenue per share TTM | 0.4790 | |
| Quarterly Revenue Growth (YOY) | 0.0000 | |
| Quarterly Earnings Growth (YOY) | -0.9680 | |
| Gross Profit (TTM) | 0 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 3.8307 | |
| Revenue Enterprise Value | 64.8544 | |
| EBITDA Enterprise Value | 0.0000 | |
| Shares | ||
| Shares Outstanding | 160,298,000 | |
| Shares Float | 127,258,941 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.00 | |
| Insider (%) | 9.22 | |
| Institutions (%) | 25.55 | |
09/04 07:00 EST - globenewswire.com
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation:
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company's participation:
09/03 14:00 EST - seekingalpha.com
Psychedelic Stock Deep Dive: Atai Life Sciences
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move.
Psychedelic Stock Deep Dive: Atai Life Sciences
After the FDA's rejection of Lykos Therapeutics' NDA for MDMA therapy, we take a more complete look at major psychedelic stocks. Atai Life Sciences is an early mover with a unique company structure and diverse pipeline that could minimize risk. Atai's stock is at historic lows, but with several upcoming Phase 2 milestones, a long-term position in ATAI could be a smart move.
08/17 08:25 EST - proactiveinvestors.com
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.
atai Life Sciences chief scientific officer details VLS-01 trial success - ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC)' chief scientific officer Dr Srinivas Rao joined Proactive to discuss the company's latest clinical trial results. Dr Rao detailed the positive outcomes from the Phase 1B trial of the VLS-01 (oral DMT) program, emphasizing the drug's excellent tolerability and potential as a best-in-class treatment option.
08/14 11:11 EST - proactiveinvestors.com
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients.
atai Life Sciences entering catalyst-rich period with key Phase2/3 trial data ahead
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has been awarded a 'Buy' rating from Jefferies analysts as the company's pipeline of mental health therapies enters a catalyst-rich period. “atai's pipeline of psychedelics (and non-psychedelics) has the potential to safely, profoundly, and durably treat tough $1 billion-plus in central nervous systems indications,” analysts wrote in a note to clients.
08/13 08:49 EST - proactiveinvestors.com
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
atai Life Sciences advances clinical pipeline in Q2, unveils positive VLS-01 trial results
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has provided an update on its research activities and told investors it has cash, marketable securities, and committed term loan funding available which is expected to fund its operations into 2026. In addition to announcing its second quarter financial results, atai on Tuesday unveiled positive preliminary Phase 1b trial results for VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
08/13 07:10 EST - globenewswire.com
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we've made significant strides to advance our pipeline, with key updates from our VLS-01 and EMP-01 programs,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai.
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE'24 • Announced clinical development plans for EMP-01 (oral R-MDMA); expect to initiate a Phase 2 study of EMP-01 in social anxiety disorder patients around YE'24 • Cash, marketable securities, and committed term loan funding expected to fund operations into 2026 NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced second quarter 2024 financial results and provided corporate updates. “Over the past quarter, we've made significant strides to advance our pipeline, with key updates from our VLS-01 and EMP-01 programs,” stated Dr. Srinivas Rao, Co-Chief Executive Officer and Co-founder of atai.
08/12 12:12 EST - marketwatch.com
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
Psychedelic drug contender stocks drop after FDA rejects MDMA treatment
Shares of companies developing treatments based on psilocybin and other psychedelic drugs moved lower on Monday after the U.S. Food and Drug Administration rejected use of MDMA for post-traumatic stress disorder.
08/07 07:00 EST - globenewswire.com
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetings Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M.
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company's participation: Format: Fireside chat and 1x1 investor meetings Date and Time: Fireside chat on Wednesday August 14 at 11:00 A.M.
07/11 13:02 EST - zacks.com
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know
atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
07/11 07:00 EST - investorplace.com
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.
3 Dirt-Cheap Drug Developers With Blockbuster Potential
One of the more exciting yet admittedly risky types of investing is buying into cheap drug developer stocks early in their company life cycle. That's because the world of drug development and biotech research tends to rely on big market-moving moments like regulatory approvals and clinical trial results.
07/08 07:45 EST - investorplace.com
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).
3 Next-Gen Drug Stocks Exploring Psychedelic Frontiers
Although psychedelic drug stocks have lost some of their earlier momentum, significant research and advancements continue under the radar. Even high-profile figures like Elon Musk reportedly use ketamine for depression, highlighting the ongoing interest in non-standard treatment protocols often associated with psychedelic stocks (though ketamine itself isn't a psychedelic, it does fall within the “alternative therapeutics” camp that psychedelic drug stocks often occupy).
07/06 07:21 EST - investorplace.com
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
3 Psychedelic Stocks to Ride to the Moon and Beyond
The value of the psychedelic market is expected to approximately triple over the next few years. While not a large market in absolute terms, that growth potential will create many winning stocks.
07/02 15:43 EST - investorplace.com
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.
3 Psychedelic Stocks to Buy on the Dip: Summer 2024
While the cannabis industry has all but become legitimate in the United States, it's not the only form of alternative medicine attempting to break through regulatory barriers. Compounds like psilocybin, lysergic acid and ketamine are all referred to as psychedelics, yet they may have medical applications which are just beginning to be explored.
06/29 10:34 EST - proactiveinvestors.com
atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. The company owned a 35.5% stake in Beckley Psytech.
atai Life Sciences CEO talks successful Phase 1 trial of IV psilocin formulation – ICYMI
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) recently welcomed encouraging results from Beckley Pystech's Phase 1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. The company owned a 35.5% stake in Beckley Psytech.
06/26 07:00 EST - globenewswire.com
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation:
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company's participation:
06/20 08:42 EST - proactiveinvestors.com
atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin.
atai Life Sciences optimistic as IV psilocin shows promise in treating depression in early trial
atai Life Sciences (NASDAQ:ATAI, ETR:9VC) has welcomed promising initial results from Beckley Psytech's Phase1 trial of its patient-protected intravenous (IV) formulation of psilocin ELE-101 in patients with major depressive disorder. Beckley Psytech, a private clinical-stage biopharmaceutical company in which atai holds a 35.5% ownership stake, reported that initial data from Phase 1 single ascending dose study in healthy participants showed that ELE-101 was well-tolerated, with no serious or severe adverse events reported, and demonstrated a dose-proportional profile, which leads to reduced variability between patients when compared to oral psilocybin.
06/20 07:00 EST - globenewswire.com
atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech's Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial results from Phase 1 and the dosing of the first patients in the Phase 2a part of the study.
atai Life Sciences Announces Update on Beckley Psytech's Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech's Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial results from Phase 1 and the dosing of the first patients in the Phase 2a part of the study.
06/07 11:09 EST - proactiveinvestors.com
atai Life Sciences poised for success with rigorous clinical trials
Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its application for MDMA-assisted therapy for post-traumatic stress disorder before the Food and Drug Administration (FDA) Advisory Committee (AdCom).
atai Life Sciences poised for success with rigorous clinical trials
Analysts at Jefferies remain bullish on atai Life Sciences (NASDAQ:ATAI, ETR:9VC) as the broader psychedelic space this week hit a “technical setback.” On June 4, Lykos Therapeutics brought its application for MDMA-assisted therapy for post-traumatic stress disorder before the Food and Drug Administration (FDA) Advisory Committee (AdCom).
05/31 07:00 EST - globenewswire.com
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQ: ATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company's management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.
05/23 08:11 EST - proactiveinvestors.com
atai Life Sciences bolsters board with two new directors
atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously served as chief operating officer of Pacira Pharmaceuticals and as a portfolio manager of JP Morgan's global healthcare fund, having started out as a practising physician.
atai Life Sciences bolsters board with two new directors
atai Life Sciences has announced the appointments of Scott Braunstein and Laurent Fischer as directors to its board. Braunstein previously served as chief operating officer of Pacira Pharmaceuticals and as a portfolio manager of JP Morgan's global healthcare fund, having started out as a practising physician.